Therapy of glioblastoma multiforme: a cumulative experience of 10 years
- PMID: 8748864
- DOI: 10.1007/BF02188776
Therapy of glioblastoma multiforme: a cumulative experience of 10 years
Abstract
Purpose: Comparison of the effect of different therapeutic modalities on survival time of patients with glioblastoma multiforme operated on during the last decade (1980-1990).
Patients and methods: The records of 157 consecutive patients with the histological diagnosis of glioblastoma multiforme were analysed for survival with respect to age of patients, extent of surgery, influence of re-operation and adjuvant postoperative treatment. The latter included fractionated radiotherapy, chemotherapy (BCNU. CCNU with Vincristine) and photodynamic therapy (PDT).
Results: Analysis of variance showed a significant effect for survival after macroscopically radical surgery (p = 0.005), postoperative radiotherapy (p < 0.001), chemotherapy (p < 0.01). Low age (p < 0.05) and a postoperative Karnofsky performance score (KPS) > or = 60 (p < 0.001) had a positive influence: the site of tumour and pre-operative presence of seizures had no significant influence (p > 0.1) on survival time.
Conclusion: We conclude that the current adequate management of glioblastoma multiforme should include surgical resection followed by adjuvant treatment such as radiotherapy and chemotherapy.
Similar articles
-
Influence of extent of surgery and tumor location on treatment outcome of patients with glioblastoma multiforme treated with combined modality approach.J Neurooncol. 1994;21(2):177-85. doi: 10.1007/BF01052902. J Neurooncol. 1994. PMID: 7861194
-
Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme.Int J Radiat Oncol Biol Phys. 2001 Jan 1;49(1):71-7. doi: 10.1016/s0360-3016(00)01458-9. Int J Radiat Oncol Biol Phys. 2001. PMID: 11163499 Clinical Trial.
-
Phase II study of accelerated fractionation radiation therapy with carboplatin followed by vincristine chemotherapy for the treatment of glioblastoma multiforme.Int J Radiat Oncol Biol Phys. 1995 Sep 30;33(2):357-64. doi: 10.1016/0360-3016(95)00160-Z. Int J Radiat Oncol Biol Phys. 1995. PMID: 7673023 Clinical Trial.
-
High-dose-rate stereotactic brachytherapy for patients with newly diagnosed glioblastoma multiformes.J Neurooncol. 2003 Jan;61(1):45-55. doi: 10.1023/a:1021270201988. J Neurooncol. 2003. PMID: 12587795 Review.
-
Favorable outcome of giant cell glioblastoma in a child. Report of an 11-year survival period.Childs Nerv Syst. 1998 Jun;14(6):288-91. doi: 10.1007/s003810050228. Childs Nerv Syst. 1998. PMID: 9694343 Review.
Cited by
-
ALA and Photofrin fluorescence-guided resection and repetitive PDT in glioblastoma multiforme: a single centre Phase III randomised controlled trial.Lasers Med Sci. 2008 Oct;23(4):361-7. doi: 10.1007/s10103-007-0494-2. Epub 2007 Oct 10. Lasers Med Sci. 2008. PMID: 17926079 Clinical Trial.
-
Standard fractionation intensity modulated radiation therapy (IMRT) of primary and recurrent glioblastoma multiforme.Radiat Oncol. 2007 Jul 14;2:26. doi: 10.1186/1748-717X-2-26. Radiat Oncol. 2007. PMID: 17629934 Free PMC article.
-
Dynamic contrast-enhanced T2-weighted MR imaging of recurrent malignant gliomas treated with thalidomide and carboplatin.AJNR Am J Neuroradiol. 2000 May;21(5):881-90. AJNR Am J Neuroradiol. 2000. PMID: 10815664 Free PMC article.
-
The importance of genomic copy number changes in the prognosis of glioblastoma multiforme.Neurosurg Rev. 2004 Jan;27(1):58-64. doi: 10.1007/s10143-003-0279-4. Epub 2003 Jul 4. Neurosurg Rev. 2004. PMID: 12845540
-
Topotecan in combination with radiotherapy in unresectable glioblastoma: a phase 2 study.J Neurooncol. 2009 Jun;93(2):253-60. doi: 10.1007/s11060-008-9774-3. Epub 2009 Jan 13. J Neurooncol. 2009. PMID: 19139825 Clinical Trial.
References
Publication types
MeSH terms
LinkOut - more resources
Medical